We supply NHS trusts with essential medicines, and use that to fund a long research programme in tissue repair, regeneration and longevity.
Three horizons, taken in sequence. Each one is the ground the next is built on.
The need is immediate and the biology is solvable. Scarring, tethering and fused tissue are problems patients live with every day because the options are sparse.
Repair restores function. Regeneration is the next level up. The step from one to the other is large and well worth pursuing.
A reduction in all-cause mortality. Exercise is currently the best preventative medicine we have; the question is what else could sit alongside it. An ambitious goal, and one for long-term development.
Tissue repair first, because the need is immediate and the treatment is solvable. Regeneration next. And finally, longevity.
The mission above is a long one. This is what pays for it, and it stands on its own terms.
We obtain Marketing Authorisations for essential medicines and supply them directly to NHS trusts.
Where supply shortages create a healthcare risk, we aim to be reliably present.
Our research programme is in fused and tethered tissue repair — scar tissue that binds surfaces together, stiffens joints and complicates healing after surgery or trauma.
It is at concept stage, with no pre-clinical data, and it is funded from trading surplus rather than from investment.
We will say more when there is data and a patent filing to say it against.
Sequence, not dates. Regulatory timing is not ours to control.
We work alongside healthcare practitioners.
EternaForge Bio is an independent company. Nothing on this page implies endorsement or affiliation by NHS England, any NHS trust, or Medicines UK.
Whether you are an NHS procurement team, a scientific collaborator, or an investor interested in what we are building — reach out directly.